Fig. 2.

In-vivoefficacy of EBL-1003 (apramycin) in comparison to gentamicin in a murine cUTI model infected with the uropathogen E. coli J96. Female C3H/HeJ mice were infected with 9.13 × 10⁸ CFU/mouse by transurethral injection in the bladder and treated subcutaneously with twice daily doses of EBL-1003 (MIC = 4 μg/mL) or gentamicin (GEN, MIC = 0.5–1 μg/mL) for three days starting 96 h post infection. (a) Dose-response multi-log CFU reduction in the kidney. One-way ANOVA and Dunnett's test of CFU reduction relative to start of treatment resulted in p< 0.05 for doses ≥0.8 mg/kg BID of EBL-1003 or gentamicin. (b) Dose-response multi-log CFU reduction in the bladder. One-way ANOVA and Dunnett's test of CFU reduction relative to start of treatment resulted in p< 0.05 for doses ≥0.2 mg/kg BID of EBL-1003 or gentamicin. Data blotted as mean ± SEM CFU reduction in n = 5 mice per dose group.